Multicenter phase 3 trial of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer

The randomized, double-blind, multicenter phase 3 GEMSTONE-302 trial in China evaluated the efficacy and safety of addition of sugemalimab (anti-PD-L1) versus placebo to first-line chemotherapy for metastatic squamous or nonsquamous non-small cell lung cancer. A prespecified interim analysis of overall survival in the trial found a significant OS benefit with sugemalimab over placebo, which was seen in most subgroups. The authors conclude that these results support the use of sugemalimab as a first-line treatment option for metastatic non-small cell lung cancer.